887results about "Amide active ingredients" patented technology

Provided herein are compositions and methods for treating patients with Usher syndrome associated retinitis pigmentosa (UARP) comprising identifying that the subject has UARP and administering to the animal or human an effective amount of an N-acetylcysteine amide (NACA) sufficient to protect vision and inhibit degradation of Ellipsoid Zone (EZ) area and retinal sensitivity. In one example, the NACA formulation is doses at 50, 100, 200, 201, 210, 225, 250, 275, 300, 350, 400, 450, 500, 600, 700, 750, 800, 900, or 1,000 mg / day.

The present invention provides compounds useful in the treatment of conditions associated with aberrant activity of voltage gated sodium channel NaV1.8, and methods of using these compounds to treat conditions such as pain, pruritus, and cough in subjects.

The invention relates to the technical field of fullerene derivatives, in particular to a structure-determined fullerene derivative, a structure-determined water-soluble fullerene derivative and preparation methods and applications of the structure-determined fullerene derivative and the structure-determined water-soluble fullerene derivative. The invention provides a fullerene derivative with a determined structure. The structural formula of the fullerene derivative is shown as (VII). The invention also provides a method for preparing the fullerene derivative with the determined structure shown as (VII). The water-soluble fullerene derivative determined by the structure as shown in (VII) provided by the invention has good water solubility and oxidation resistance.

The invention belongs to the technical field of plant care essential oil extraction, and particularly relates to sanshool delayed care essential oil and a preparation method thereof. The invention discloses a sanshool-enriched lipid composition which is prepared from the following components in parts by weight: 0.05 to 0.1 part of sanshool-enriched fraction, 1 to 2 parts of solid lipid, 1 to 1.5 parts of liquid lipid, 1.5 to 2.5 parts of stable surfactant, 1 to 2 parts of cosurfactant, 3 to 5 parts of glycerol, 0.2 to 0.5 part of soothing anti-irritation component, 0.05 to 0.1 part of sodium hyaluronate, 0.1 to 0.3 part of hydroxypropyl methyl cellulose, 0.05 to 0.1 part of antioxidant and the balance of purified water. According to the invention, sanshool is used as a core functional factor, and through collaborative design of supercritical extraction, molecular distillation purification, NLC carrier encapsulation and a soothing film-forming system, contradictions of effectiveness, mildness and the like in an existing scheme are solved, and mild desensitization, stable controlled release, reduction of stimulation and migration risks and improvement of tolerance and action consistency are realized.

A method for treating liver cancer, in particular in subjects exhibiting homologous recombination deficiency (HRD) positive, comprises the use of hydroxyurea methyl acyl fulvene. The compounds may be administered as monotherapy or in combination with other chemotherapeutic agents and / or radiation therapy.

The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity. The composition of the invention comprises one or more nicotine sources, one or more buffering agents,5 and at least two antagonists in an effective amount to inhibit or block nicotine agonist activation of Nicotinic Acetylcholine Receptors (nAChR) and / or Transient Receptor Potential (TRP) ion channels, the at least two antagonists being selected from the group consisting of a first antagonist comprising camphor or one or more compounds resembling camphor, a second antagonist comprising eucalyptol, and a 10 third antagonist comprising (1R,2S,5R)-N-(4-Methoxyphenyl)-5-methyl-2-(1- methylethyl)cyclohexanecarboxamide (WS-12).

To provide an excellent pest control agent 【Solution means】General formula [I] 【Chemical formula 1】 JPEG2026077605000071.jpg4066[wherein, R 1 , R 4 each independently represents a substituent such as an alkyl group, R 2 , R 3 , R 5 each independently represents a hydrogen atom or a substituent such as an alkyl group, and R 6 represents a hydrogen atom or a halogen atom.]. Provided are N-benzylamide compounds represented by the formula or salts thereof, and pest control agents containing them as active ingredients.

The present disclosure describes methods of specifically modulating the activity and / or number of regulatory T (Treg) cells within a tumor in a subject. Such methods may be used to reduce the number of regulatory T cells within a tumor in a subject, as well as to inhibit tumor growth in a subject with cancer without eliciting an autoimmune response. This method relies on the inhibition of CD36 or PPARbeta.

The present invention relates to a pharmaceutical liquid composition, wherein said liquid composition comprises at least one cooling agent comprising of a phenyl ring containing a polar side group at least one viscosity enhancing agent and at least one surfactant. The invention also relates to a method to produce such a pharmaceutical composition as well as a method of alleviating a symptom selected from the group consisting of cough, nasal congestion and sore throat in a subject comprising administering the composition according to any of preceding claims.

The present application provides compositions comprising an endoplasmic reticulum / sarcoplasmic reticulum calcium channel inhibitor and a gap junction inhibitor for use in various methods, such as methods for treating or preventing necrosis, cell death, tissue damage, or organ damage. The compositions may also comprise a cell membrane calcium channel inhibitor and / or a calcium chelator. Also provided are compositions comprising a calpain inhibitor and a cathepsin inhibitor for use in various methods. Furthermore, compositions comprising a calcium chelator, preferably at a relatively high dose, for use in various methods are provided.

The present invention relates to new inhibitors of the transcription factor FOXA1 and / or FOXA2 for use in a method of treatment of cancer or other FOXA1 / FOXA2-dependent diseases.

The present disclosure provides compounds of Formula (I), their pharmaceutically acceptable salts, and pharmaceutical compositions thereof, which relate to novel DNA polymerase γ (POLγ) modulators.

In certain embodiments, Formula I: 【Chemical 1】 Compounds of JPEG2025520456000046.jpg5339 or pharmaceutically acceptable salts or solvates thereof, compositions comprising a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, and their use in the treatment of certain diseases or disorders (e.g., cancer, fibrosis, chronic inflammation) etc. are provided herein.

The present invention relates to sulforaphane glycoconjugate compounds, as well as to the synthesis and therapeutic uses thereof for treating inflammatory diseases.

Provided herein are compositions and methods for treating, inhibiting and / or reducing the severity of neuroblastoma, small cell lung cancer (SCLC), large cell neuroendocrine cancer (LCNEC), large-cell carcinoma (LCC), squamous cell carcinoma (SqCC), and / or adenocarcinoma (AC) in subjects in need thereof. The methods include providing an agent that inhibits expression or activity of ONECUT2 and administering a therapeutically effective amount of the agent so as to treat, inhibit and / or reduce the severity of neuroblastoma, small cell lung cancer (SCLC), large cell neuroendocrine cancer (LCNEC), large-cell carcinoma (LCC), squamous cell carcinoma (SqCC), and / or adenocarcinoma (AC) in the subject.

This invention provides the application of CTH inhibitors and / or xCT inhibitors in the preparation of drugs for inhibiting mammalian embryo implantation, relating to the field of pharmaceutical technology. This invention verifies the efficacy of cystathionine-γ-lyase (CTH) inhibitors and / or solute carrier family 7 member 11 (xCT) inhibitors in inhibiting mammalian embryo implantation. The results show that xCT inhibitors and / or CTH inhibitors can significantly inhibit the proliferation of luteinized granulosa cells and progesterone secretion in mouse models. Furthermore, in vivo injection of xCT inhibitors and / or CTH inhibitors into mouse models not only significantly inhibits ovulation and the maturation rate of released oocytes, but also significantly reduces the formation of functional corpus luteum and embryo implantation. Therefore, this application provides new ideas and methods for the development of contraceptive drugs.

The present disclosure relates to a method for preparing a veterinary medicament dosage using a 3D printer. The method comprises printing a plurality of layers comprising one or more active pharmaceutical ingredients (APIs) on the printing substrate, so that each layer comprising API is surrounded by layers comprising one or more taste masking agents, until a required dose of the one or more APIs is obtained. The disclosure also relates to a veterinary medicament dosage obtainable by the method.

A rinsing solution for photodynamic disinfection, in particular oral disinfection, including, at least one photosensitiser from the group comprising riboflavin 5′-phosphate sodium in a proportion of 0.2 to 0.6 wt. % and a photosensitiser other than riboflavin 5′-phosphate sodium in a proportion of 0.001 to 0.05 wt. %, at least one viscosity modulator from the group comprising glycerol in a proportion of 1.0 to 5.0 wt. % and hyaluronic acid sodium salt in a proportion of 0.01 to 0.3 wt. %, at least one biofilm inhibitor from the group comprising xylitol in a proportion of 7.0 to 25.0 wt. %, L-arginine in a proportion of 0.01 to 0.5 wt. % and urea in a proportion of 0.5 to 3.0 wt. %, with the remainder on a water base.

A method for treating cancer comprises the combined use of a therapeutically effective amount of elzovtinib or an elzovtinib analog, a derivative thereof, or a pharmaceutically acceptable salt, and a therapeutically effective amount of bortezomib, ibrutinib, or an analog, derivative, or pharmaceutically acceptable salt thereof. The composition and kit are included herein. The cancer may be refractory to bortezomib and / or ibrutinib.

An object of the present invention is to provide a small molecule compound (IL-17 activity inhibitor) having a more potent inhibitory effect on IL-17 activity than conventional compounds. The IL-17RA inhibitor of the present invention is, for example, a small molecule compound surrounded by Phe60, Gln87, Asp121, Pro122, Asp123, Gln124, Asp153, Cys154, Glu155, Lys160, Pro164, Cys165, Ser167, Ser168, Gly169, Ser170, Leu171, Trp172, Asp173, Pro174, Pro254, Phe256, Ser258, Cys259, Asp262, Cys263, Leu264, and His266, which are contained in the extracellular domain of human interleukin-17 receptor A (IL-17RA). The compound contains a compound having the effect of inhibiting the binding of interleukin-17A (IL-17A) to IL-17RA in humans, etc., or a pharmaceutically acceptable salt, solvate, or prodrug thereof, which can bind to IL-17RA through non-covalent interactions, including van der Waals forces acting between at least 13 of these amino acid residues in the space defined by the compound, and preferably further including at least one type of intermolecular interaction selected from the group consisting of ionic bond, hydrogen bond, C-H-π interaction, and hydrophobic interaction acting between predetermined ones of the amino acid residues.

To provide an agent for treating malignant mesothelioma that can kill specifically cancer cells and has few adverse effects.SOLUTION: An agent for treating malignant mesothelioma contains cerulenin and / or a derivative thereof or KN-93 and / or a derivative thereof as an active ingredient.SELECTED DRAWING: None

The present invention provides methods of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof comprising intravenously administering sotalol hydrochloride to a subject in need thereof. Embodiments of the present invention further provide novel methods of intravenously administering sotalol hydrochloride for example in pediatric patients. The present invention provides a novel intravenous, prophylactic, antiarrhythmic method of sotalol administration.

Use of N-oleoylethanolamide(OEA) or a microbiota OEA producer, such as Eubacterium rectale, in the preparation of medicament for the treatment of irritable bowel syndrome (IBS).

Provided is a novel ceramide composition. Specifically, provided is a ceramide composition extracted from a chicken leg by means of ethanol.

The present disclosure provides pharmaceutical formulations of the compound of Formula (I), Formula (la), or Formula (lb), or a pharmaceutically acceptable salt thereof, and an aqueous vehicle. The pharmaceutical formulations of the disclosure are useful in treatment and prevention of viral infections in subjects in need thereof and are for administration by inhalation.

The features of the present invention for providing a novel neutrophil activator are as follows. 1. An IL-8 production accelerator containing at least one selected from GlcCer[d18:2(4E,8Z) / 18:0], GlcCer[d18:2(4E,8Z) / 20:0], GlcCer[d18:2(4E,8Z) / 22:0], GlcCer[d18:2(4E,8Z) / 24:0], and GlcCer[d18:2(4E,8Z) / 26:0] as an active ingredient. 2. An IL-8 production accelerator containing GlcCer[d18:2(4E,8E) / 24:0] as an active ingredient. 3. An IL-8 production accelerator containing at least one selected from GlcCer[t18:1(8Z) / 24:0] and GlcCer[t18:1(8Z) / 26:0] as an active ingredient. 4. An IL-8 production accelerator containing GlcCer[d18:1(4E) / 20:0] as an active ingredient. 5. An IL-8 production accelerator containing at least one selected from Cer(t18:0 / 22:0), Cer(t18:0 / 23:0), Cer(t18:0 / 24:0), Cer(t18:0 / 25:0), and Cer(t18:0 / 26:0) as an active ingredient. 6. An IL-8 production accelerator containing at least one selected from Cer[t18:1(8Z) / 24:0] and Cer[d18:2(4E,8Z) / 20:0] as an active ingredient. 7. An IL-8 production accelerator containing at least one selected from Oryza Ceramide A, Oryza Ceramide B, and Oryza Ceramide C as an active ingredient.

The application discloses an epoxy compound and application thereof, and particularly discloses an epoxy compound as shown in formula I, a pharmaceutically acceptable salt or a stereoisomer thereof and application thereof. The compound has high inhibitory activity on beta5i and beta1i, and has low inhibitory level on beta5c and beta1c, the compound has high selectivity, and can be used for treating autoimmune diseases.

An object of the present invention is to provide a cacao derived composition containing a free ceramide, as well as a moisturizing agent, a skin quality improving agent, a hair quality improving agent, a cosmetic for skin, a cosmetic for hair, a pharmaceutical composition and a food composition each containing the cacao derived composition, and the present invention provides a cacao derived composition containing a cacao derived free ceramide, wherein the amount of the cacao derived free ceramide is 1.2% by mass or more based on the mass of the cacao derived composition, as well as a moisturizing agent, a skin quality improving agent, a hair quality improving agent, a cosmetic for skin, a cosmetic for hair, a pharmaceutical composition and a food composition each containing the cacao derived composition.

The present invention relates to a nasal ointment comprising hyaluronic acid, dexpanthenol and an aloe vera extract. The present invention also relates to the use of hyaluronic acid, dexpanthenol and an aloe vera extract for manufacturing an agent used in various medical procedures. The invention also relates to a method for the preparation of said nasal ointment.